H Meden
Overview
Explore the profile of H Meden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naser B, Castelo-Branco C, Meden H, Minkin M, Rachon D, Beer A, et al.
Climacteric
. 2021 Oct;
25(3):220-227.
PMID: 34608830
Weight gain is a frequent problem in perimenopausal and postmenopausal women. (CR) is a popular treatment option for menopausal symptoms. The aim of this review was to investigate whether there...
2.
3.
Marx D, Uebel T, Schauer A, Kuhn W, Meden H
Oncol Rep
. 2011 May;
4(6):1157-60.
PMID: 21590212
Sera from 130 ovarian cancer patients and from 118 normal control volunteers were assayed for serum autoantibodies to p53 using an enzyme-linked immunosorbent assay (ELISA). Overall, autoantibodies were detected in...
4.
Marx D, Meden H
Methods Mol Med
. 2011 Feb;
39:687-91.
PMID: 21340831
The deregulation of the balance between proliferation and programmed cell death is considered one of the most important features of malignant tumors. The search for new markers, which may reflect...
5.
Meden H, Fattahi-Meibodi A, Marx D
Methods Mol Med
. 2011 Feb;
39:125-33.
PMID: 21340763
The most important prognostic parameters for gynecologic malignancies are tumor stage, residual tumor after surgical treatment, histological subtype, and degree of malignancy (1-2). However, these factors present an incomplete picture...
6.
Henneicke-von Zepelin H, Meden H, Kostev K, Schroder-Bernhardi D, Stammwitz U, Becher H
Int J Clin Pharmacol Ther
. 2007 Apr;
45(3):143-54.
PMID: 17416109
Objective: To investigate the influence of an isopropanolic Cimicifuga racemosa extract (iCR) on recurrence-free survival after breast cancer, including estrogen-dependent tumors. Methods: This pharmacoepidemiologic observational retrospective cohort study examined breast...
7.
Breitbach G, Meden H, Schmid H, Kuhn W, Sass G, Schach S, et al.
Anticancer Res
. 2003 Jan;
22(5):2923-32.
PMID: 12530019
Background: In August 1988 a randomised phase III multicenter trial was started in order to compare cisplatinum/treosulfan (PT) with standard cisplatinum/cyclophosphamide (PC) in advanced ovarian carcinoma, aiming at lower toxicity...
8.
Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M
Anticancer Res
. 2001 Jun;
21(2B):1301-5.
PMID: 11396203
Background: In patients with HER2-positive metastatic breast cancer (MBC), combined treatment of herceptin (H) and chemotherapy (CT) improves time to progression, response rates and survival compared with CT alone. Materials...
9.
Marx D, Frey M, Zentgraf H, Adelssen G, Schauer A, Kuhn W, et al.
Cancer Detect Prev
. 2001 May;
25(2):117-22.
PMID: 11341346
Sera from 99 ovarian cancer patients were assayed for serum autoantibodies to p53 using a newly developed enzyme-linked immunosorbent assay (ELISA). Results were compared to the investigation using the former...
10.
Zupancic K, Meden H, Tomazevic T, Znidarsic V
J Assist Reprod Genet
. 2001 Jan;
17(9):496-7.
PMID: 11155321
No abstract available.